Observational Study on the Treatment of Patients With Metastatic Breast Cancer

HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes

NCT04396626 ·Status: TERMINATED

Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer

NCT00660803 ·Status: COMPLETED

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

NCT04807595 ·Status: COMPLETED

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

NCT06344793 ·Status: COMPLETED

Metastases Directed Therapy for Oligometastatic Breast Cancer

NCT06144346 ·Status: RECRUITING ·Phase: NA

A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

NCT06791161 ·Status: ENROLLING_BY_INVITATION

Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States

NCT07342309 ·Status: ACTIVE_NOT_RECRUITING

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

NCT06040593 ·Status: COMPLETED

Observation of Medical Treatments in MBC HER2-negative Patients

NCT02365831 ·Status: UNKNOWN

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NCT02364557 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

NCT04993014 ·Status: RECRUITING ·Phase: PHASE2

HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

NCT05913440 ·Status: COMPLETED

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

NCT06231693 ·Status: TERMINATED

Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)

NCT01329640 ·Status: TERMINATED ·Phase: PHASE2

Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

NCT00820690 ·Status: UNKNOWN

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

NCT02684032 ·Status: COMPLETED ·Phase: PHASE1

Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer

NCT01392586 ·Status: TERMINATED ·Phase: PHASE3

Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

NCT04126525 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery

NCT00305825 ·Status: COMPLETED ·Phase: PHASE2

Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study

NCT02393924 ·Status: COMPLETED

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

NCT00679341 ·Status: COMPLETED ·Phase: PHASE2

Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis

NCT02560311 ·Status: UNKNOWN

Effect of Neoadjuvant Chemoradiation on Pathologic Complete Response Rates in Locally Advanced Breast Cancer Patients

NCT06631066 ·Status: COMPLETED ·Phase: NA

HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

NCT06125314 ·Status: COMPLETED

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

NCT05076695 ·Status: UNKNOWN ·Phase: PHASE2